Tyrosine Kinase Inhibitor Sunitinib Delays Platelet-Induced Coagulation: Additive Effects of Aspirin

Abstract

Background Sunitinib is a multitarget tyrosine kinase inhibitor (TKI) used for cancer treatment. In platelets, sunitinib affects collagen-induced activation under noncoagulating conditions. We investigated (1) the effects of sunitinib on thrombus formation induced by other TK-dependent receptors, and (2) the effects under coagulating conditions. Cardiovascular disease is a comorbidity in cancer patients, resulting in possible aspirin treatment. Sunitinib and aspirin are associated with increased bleeding risk, and therefore we also investigated (3) the synergistic effects of these compounds on thrombus and fibrin formation.

Methods Blood or isolated platelets from healthy volunteers or cancer patients were incubated with sunitinib and/or aspirin or vehicle. Platelet activation was determined by TK phosphorylation, flow cytometry, changes in [Ca²⁺]_i, aggregometry, and whole blood perfusion over multiple surfaces, including collagen with(out) tissue factor (TF) was performed.

Results Sunitinib reduced thrombus formation and phosphatidylserine (PS) exposure under flow on collagen type I and III. Also, sunitinib inhibited glycoprotein VI-induced TK phosphorylation and Ca²⁺ elevation. Upon TF-triggered coagulation, sunitinib decreased PS exposure and fibrin formation. In blood from cancer patients more pronounced effects of sunitinib were observed in lung and pancreatic as compared to neuroglioblastoma and other cancer types. Compared to sunitinib alone, sunitinib plus aspirin further reduced platelet aggregation, thrombus formation, and PS exposure on collagen under flow with(out) coagulation.

Conclusion Sunitinib suppresses collagen-induced procoagulant activity and delays fibrin formation, which was aggravated by aspirin. Therefore, we urge for awareness of the combined antiplatelet effects of TKIs with aspirin, as this may result in increased risk of bleeding.

Keywords

platelets - thrombus - tyrosine kinase inhibitor - sunitinib - procoagulant activity - aspirin

• References

• 1 Goodman VL, Rock EP, Dagher R. et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007; 13 (05) 1367-1373
• 2 Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 2007; 29 (07) 1338-1353
• 3 Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009; 10 (10) 967-974
• 4 Versteeg HH, Heemskerk JW, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev 2013; 93 (01) 327-358
• 5 Sabrkhany S, Griffioen AW, Pineda S. et al. Sunitinib uptake inhibits platelet function in cancer patients. Eur J Cancer 2016; 66: 47-54
• 6 Walraven M, Homs MYV, van der Veldt AAM. et al. Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab. Angiogenesis 2018; 21 (02) 325-334
• 7 De Stefano V. Arterial thrombosis and cancer: the neglected side of the coin of Trousseau syndrome. Haematologica 2018; 103 (09) 1419-1421
• 8 Navi BB, Reiner AS, Kamel H. et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 2017; 70 (08) 926-938
• 9 Silvain J, Cayla G, O'Connor SA, Collet JP, Montalescot G. Antiplatelet options for secondary prevention in acute coronary syndromes. Expert Rev Cardiovasc Ther 2011; 9 (11) 1403-1415
• 10 Arthur JF, Jandeleit-Dahm K, Andrews RK. Platelet hyperreactivity in diabetes: focus on GPVI signaling-are useful drugs already available?. Diabetes 2017; 66 (01) 7-13
• 11 Gresele P, Momi S, Malvestiti M, Sebastiano M. Platelet-targeted pharmacologic treatments as anti-cancer therapy. Cancer Metastasis Rev 2017; 36 (02) 331-355
• 12 Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The platelet lifeline to cancer: challenges and opportunities. Cancer Cell 2018; 33 (06) 965-983
• 13 van der Meijden PE, Feijge MA, Giesen PL, Huijberts M, van Raak LP, Heemskerk JW. Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk. Thromb Haemost 2005; 93 (06) 1128-1136
• 14 Feijge MA, van Pampus EC, Lacabaratz-Porret C. et al. Inter-individual variability in Ca2+ signalling in platelets from healthy volunteers: effects of aspirin and relationship with expression of endomembrane Ca2+-ATPases. Br J Haematol 1998; 102 (03) 850-859
• 15 Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260 (06) 3440-3450
• 16 Chirumamilla CS, Fazil MHUT, Perez-Novo C. et al. Profiling activity of cellular kinases in migrating T-cells. Methods Mol Biol 2019; 1930: 99-113
• 17 Heemskerk J, de Witt S, Swieringa F, Cosemans J. Multi-parameter assessment of thrombus formation on microspotted arrays of thrombogenic surfaces (protocol no. 3382). Nat Prot Exchange. 2014.
• 18 Swieringa F, Baaten CC, Verdoold R. et al. Platelet control of fibrin distribution and microelasticity in thrombus formation under flow. Arterioscler Thromb Vasc Biol 2016; 36 (04) 692-699
• 19 Numakura K, Fujiyama N, Takahashi M. et al. Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients. Oncotarget 2018; 9 (38) 25277-25284
• 20 Swieringa F, Kuijpers MJ, Heemskerk JW, van der Meijden PE. Targeting platelet receptor function in thrombus formation: the risk of bleeding. Blood Rev 2014; 28 (01) 9-21
• 21 Tullemans BME, Heemskerk JWM, Kuijpers MJE. Acquired platelet antagonism: off-target antiplatelet effects of malignancy treatment with tyrosine kinase inhibitors. J Thromb Haemost 2018; 16 (09) 1686-1699
• 22 de Witt SM, Swieringa F, Cavill R. et al. Identification of platelet function defects by multi-parameter assessment of thrombus formation. Nat Commun 2014; 5: 4257
• 23 Guidetti GF, Torti M, Canobbio I. Focal adhesion kinases in platelet function and thrombosis. Arterioscler Thromb Vasc Biol 2019; 39 (05) 857-868
• 24 Fernández DI, Kuijpers MJE, Heemskerk JWM. Platelet calcium signaling by G-protein coupled and ITAM-linked receptors regulating anoctamin-6 and procoagulant activity. Platelets 2021; 32 (07) 863-871
• 25 Rayes J, Watson SP, Nieswandt B. Functional significance of the platelet immune receptors GPVI and CLEC-2. J Clin Invest 2019; 129 (01) 12-23
• 26 Hemker HC, Giesen P, AlDieri R. et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32 (5-6): 249-253
• 27 Qiang H, Chang Q, Xu J. et al. New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer. J Cancer Res Clin Oncol 2020; 146 (03) 631-645
• 28 Faivre S, Niccoli P, Castellano D. et al. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol 2017; 28 (02) 339-343
• 29 Grisanti S, Ferrari VD, Buglione M. et al; Gruppo Neuro-Oncologico Bresciano. Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature. J Neurosurg Sci 2019; 63 (04) 458-467
• 30 Inoue O, Suzuki-Inoue K, Dean WL, Frampton J, Watson SP. Integrin alpha2beta1 mediates outside-in regulation of platelet spreading on collagen through activation of Src kinases and PLCgamma2. J Cell Biol 2003; 160 (05) 769-780
• 31 Kuijpers MJ, Pozgajova M, Cosemans JM. et al. Role of murine integrin alpha2beta1 in thrombus stabilization and embolization: contribution of thromboxane A2. Thromb Haemost 2007; 98 (05) 1072-1080
• 32 Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6 (09) 734-745
• 33 Karaman MW, Herrgard S, Treiber DK. et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26 (01) 127-132
• 34 Jooss NJ, De Simone I, Provenzale I. et al. Role of platelet glycoprotein VI and tyrosine kinase Syk in thrombus formation on collagen-like surfaces. Int J Mol Sci 2019; 20 (11) E2788
• 35 Auger JM, Kuijpers MJ, Senis YA, Watson SP, Heemskerk JW. Adhesion of human and mouse platelets to collagen under shear: a unifying model. FASEB J 2005; 19 (07) 825-827
• 36 Rainer PP, Doleschal B, Kirk JA. et al. Sunitinib causes dose-dependent negative functional effects on myocardium and cardiomyocytes. BJU Int 2012; 110 (10) 1455-1462
• 37 Diaz-Ricart M, Palomo M, Fuste B. et al. Inhibition of tyrosine kinase activity prevents the adhesive and cohesive properties of platelets and the expression of procoagulant activity in response to collagen. Thromb Res 2008; 121 (06) 873-883
• 38 van Geffen JP, Kleinegris MC, Verdoold R. et al. Normal platelet activation profile in patients with peripheral arterial disease on aspirin. Thromb Res 2015; 135 (03) 513-520
• 39 Li R, Diamond SL. Detection of platelet sensitivity to inhibitors of COX-1, P2Y₁, and P2Y₁₂ using a whole blood microfluidic flow assay. Thromb Res 2014; 133 (02) 203-210
• 40 Hosokawa K, Ohnishi T, Sameshima H. et al. Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions. Thromb Haemost 2013; 109 (01) 102-111
• 41 Bossavy JP, Thalamas C, Sagnard L. et al. A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. Blood 1998; 92 (05) 1518-1525
• 42 Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen K, Boneu B. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000; 101 (24) 2823-2828
• 43 Mendolicchio GL, Zavalloni D, Bacci M. et al. Variable effect of P2Y12 inhibition on platelet thrombus volume in flowing blood. J Thromb Haemost 2011; 9 (02) 373-382
• 44 André P, LaRocca T, Delaney SM. et al. Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis. Circulation 2003; 108 (21) 2697-2703
• 45 Sakakibara M, Goto S, Eto K, Tamura N, Isshiki T, Handa S. Application of ex vivo flow chamber system for assessment of stent thrombosis. Arterioscler Thromb Vasc Biol 2002; 22 (08) 1360-1364
• 46 Ninomoto J, Mokatrin A, Kinoshita T. et al. Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction. Hematology 2020; 25 (01) 112-117
• 47 Sheth RA, Niekamp A, Quencer KB. et al. Thrombosis in cancer patients: etiology, incidence, and management. Cardiovasc Diagn Ther 2017; 7 (Suppl. 03) S178-S185
• 48 Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood 2017; 130 (13) 1499-1506
• 49 Sabrkhany S, Kuijpers MJE, van Kuijk SMJ. et al. A combination of platelet features allows detection of early-stage cancer. Eur J Cancer 2017; 80: 5-13
• 50 Best MG, Sol N, Kooi I. et al. RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell 2015; 28 (05) 666-676